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Abstract: The scale-up of antiretroviral therapy is progressing rapidly in Africa but with a limited evidence-base. We re-
port the baseline results from a large pragmatic cluster-randomised trial comparing different strategies of ART delivery. 
The trial is integrated in normal health service delivery. 
1453 subjects were recruited into the study. Significantly more women (71%) than men (29%) were recruited. The WHO 
HIV clinical stage at presentation did not differ significantly between men and women: 58% and 53% respectively were at 
WHO stage III or IV (p=0.9). Median CD4 counts (IQR) x 10
6cells/l were 98 (28, 160) among men and 111 (36, 166) 
among women. Sixty-four percent of women and 61% men had plasma viral load 100,000 copies. Baseline characteris-
tics did not change over time. 
Considerably fewer men than women presented for treatment. Both men and women presented at an advanced stage with 
very low median CD4 count and high plasma viral load. 
Keywords: Cluster-randomised trial, antiretroviral therapy, effectiveness trial, Africa, Home-based HIV care, baseline charac-
teristics, equity. 
INTRODUCTION 
  Antiretroviral therapy (ART) is being scaled-up in Africa 
but the number of people receiving treatment remains far 
less than those needing treatment [1]. Major factors inhibit-
ing scale-up include the severe shortage of clinical staff and 
the restricted access to care due to unavailability or high ex-
pense of transportation [2]. There is an urgent need to iden-
tify effective models of HIV care that rely less on the exper-
tise of clinical staff, that minimise the demands on existing 
health services and that do not require patients to travel long 
distances [3]. What these models should comprise and how 
they should be evaluated is less clear. 
  Home-based HIV care, involving drug delivery, monitor-
ing and support of clients in the home by non-clinically 
qualified staff, could be an important strategy in selected 
settings [4]. However, it is uncertain as to whether non-
clinical personnel can monitor clients on ART adequately 
and will make referrals for medical care appropriately. Also, 
regular home visits may be unacceptable because of HIV-
related stigma, may be difficult to sustain when clients be-
come healthy and resume mobile lifestyles, and may not be 
cost-effective. 
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  World Health Organization estimates suggest that an ap-
proximately equal number of men and women have been 
able to access ART thus far [1], but these estimates are de-
rived largely from programmes based in urban centres where 
most ART roll-out has occurred. Understanding the charac-
teristics of those who access ART in rural and semi-urban 
areas will be vital in order to assess equity. 
  We have started a randomised trial in Uganda to compare 
home-based with the standard facility-based ART delivery. 
Here we report on the design considerations and baseline 
results for men and women. 
METHODS 
  The trial is based at The AIDS Support Organisation 
(TASO) clinic in Jinja, South-East Uganda and is being con-
ducted in real life health service conditions with TASO staff 
responsible for all service delivery. TASO is by far the larg-
est provider of ART in the area. Registration at TASO is free 
for all HIV-infected adults and children. HIV-infected pa-
tients were screened for eligibility for ART from August 
2004 and recruitment into the TASO ART programme ended 
in December 2006 when the available funds had been used 
up. Patients who had been with the organisation the longest 
were given priority during the first year of the programme 
and thereafter ART was made available to all on a first come 
first served basis. Recruitment into the trial began in Febru-
ary 2005 and ended in December 2006 when TASO stopped 
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old in whom ART was initiated were invited to join the trial 
except those living well outside the catchment population or 
on islands which were more than 100 kilometres away and 
where provision of home-based care is difficult for TASO. 
No financial or other incentives to join the trial were pro-
vided by the research staff and TASO clinical management 
procedures were identical for trial participants and non-trial 
participants. Follow-up in the trial is scheduled to end in 
2008. 
  Patients were assessed and prepared for ART by TASO 
staff over 3 visits to clinic which were usually spread over 4-
8 weeks. Those at WHO late stage III (chronic fever of un-
known origin, chronic diarrhoea of unknown origin, oral 
hairy leukoplakia and pyomyositis), stage IV, or with CD4 
count less 200 x10
6/l were offered ART in accordance with 
Ministry of Health guidelines. The first line regimen com-
prised either zidovudine or stavudine, lamivudine, and either 
nevirapine or efavirenz. Clients were provided with drugs to 
cover 28 days of treatment and issued with a 7-day pill box 
(with compartments for morning and evening doses), and 
trained to transfer the pills from the packets into the pill box. 
A buffer supply of two days was also provided. Patients 
were also encouraged strongly to have a medicine compan-
ion for support and reminders. 
  The trial is cluster randomised, comparing two strategies. 
Treatment was initiated at the TASO Jinja clinic. Patients 
were then randomised to either home-based or facility-based 
ART. For those receiving home-based treatment, field offi-
cers deliver drugs at home monthly, monitor patients using a 
checklist and provide adherence support. They refer clients 
to see a physician at the TASO clinic when judged neces-
sary. Field officers have mobile phones and discuss cases 
with TASO physicians when they are unclear whether or not 
to refer. If a client misses a follow-up appointment, the 
fieldworker returns to the home, usually the next day. If the 
client is not at home the second time, the fieldworker will 
leave a message for the client to come to the TASO clinic in 
Jinja. In addition, clients are asked to come to clinic for rou-
tine clinical and counselling reviews at 2 and 6 months after 
starting therapy and 6-monthly thereafter. In the facility-
based arm, clients collect drugs from the pharmacy at the 
TASO clinic monthly and are seen by a nurse who refers 
them to a doctor or counsellor if necessary. Clients are also 
assessed routinely every 3 months by a counsellor and a phy-
sician. Clients who miss an appointment are followed-up at 
home by a fieldworker, usually after 2-3 days, and reminded 
to attend clinic (provided that the client has given permission 
for home visits to be conducted). 
  Clients receiving either mode of care can come to the 
TASO clinic at anytime they feel unwell. They also have 
access to a telephone hotline. In exceptional cases, when a 
client is bed-ridden and unable to travel, home-care is pro-
vided by a TASO team including a physician. CD4 count 
monitoring is done 6-monthly for all clients. Blood is taken 
for plasma viral load testing, also 6-monthly, but this testing 
is for research purposes and is done in batches rather than in 
real-time. 
  Alongside the provision of ART, TASO offers free vol-
untary counselling and testing (VCT) to family members of 
clients on ART. In the facility-based arm, clients are given  
 
vouchers for their family members to use at the TASO clinic 
for VCT. In the home-based arm, VCT is offered in the 
home at ART initiation or during routine drug delivery visits. 
  The evaluation was conducted by researchers who were 
not involved with service delivery. Subjects were inter-
viewed by research staff in private rooms before being seen 
by TASO clinical staff. Questionnaires were translated into 
the local language, Luganda, back-translated to English by 
an independent person unaware of the original English ver-
sion and cross-checked. All data were double-entered. 
Analyses were conducted using robust survey analysis pro-
cedures that took the clustering due to the study design into 
account. For categorical variables, the Pearson chi-square 
statistic for two-way tables was adjusted into an F-statistic 
with non-integer degrees of freedom, using a second order 
correction due to Rao and Scott (1981, 1984). For continu-
ous variables, a t-test was done by finding the ratio of the 
difference of the subgroup mean values to the standard error 
of this difference, with the standard error being estimated 
using standard linearization methods for variances in com-
plex surveys. Analyses were done using the statistical pack-
age STATA release 9. 
  The trial protocol was approved by the Ugandan National 
Council of Science and Technology and the Institutional 
Review Boards of the Uganda Virus Research Institute, US 
Centers for Disease Control and Prevention and London 
School of Hygiene & Tropical Medicine. 
Trials Endpoints and Sample Size 
  The trial is designed to test the hypothesis that the effec-
tiveness of home-based care will be approximately equiva-
lent to that of the facility-based care. Following the initiation 
of therapy, it is expected that the plasma viral load will fall 
rapidly [5] below detectable limits since this population is 
almost entirely ART naïve. The primary endpoint is the time 
for a plasma viral load exceeding 500 copies per ml. Major 
secondary endpoints include cost-effectiveness and medica-
tion adherence. 
  We assumed that the rate of viral load failure in the facil-
ity-based arm would be 10 per 100 person-years at risk. A 
trial of 40 clusters and 30 subjects per cluster (and a coeffi-
cient of variation of 0.2) would provide over 90% power to 
show that the 95% two-sided confidence interval for the dif-
ference between the two arms in the rate of viral load failure 
lies between ± 3.33 per 100 person-years [6]. 
Randomisation 
  A cluster was defined as a geographical area, usually a 
sub-county, town, village or a group of villages. Larger areas 
(e.g. Jinja Town) were divided into more than one cluster, 
with division made according to major barriers (e.g. a high-
way). Forty-four geographical areas were defined and ran-
domised in 9 strata according to the estimated number of 
HIV-infected clients and distance from TASO Jinja. 
RESULTS 
  4560 adult subjects were screened by TASO. Their me-
dian age was 37 (IQR 31, 42) years and 3,368 (74%) were 
women. Overall, 2636 (54%) subjects were eligible for ART 
and ART was initiated in 1,889 (41%). The others did not  
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Table 1.  Characteristics of Men and Women at Baseline 
 
  Men Women   
Number recruited (%)  422 (29)  1,031 (71)    
      
Age in years, median (IQR)  40 (34-47)  37 (31-42)  P< 0.0001 
      
Education level, number (%)       
No education  31 (7)  203 (20)   P< 0.0001 
Primary  223 (53)  593 (57)   
Secondary  142 (34)  207 (20)   
Tertiary  26 (6)  28 (3)   
      
Marital status, number (%)       
Currently married/living with someone  279 (66)  237 (23)  P <0.0001 
Widowed  53 (13)   530 (51)   
Separated /divorced  86 (20)   245 (24)   
Single/ never married  4 (1)   19 (2)   
      
Clients’ main occupation, number (%)       
Business/self employed  127 (30)  364 (35)  P< 0.0001 
Professional  67 (16)   58 (6)   
Farmer  119 (28)  269 (26)   
Unemployed  102 (24)  294 (29)   
Housewife 0  38  (4)   
Other  7 (2)   8 (1)   
      
Family owns house, number (%)  231 (55)  462 (45)  P< 0.004 
      
Client’s monthly income       
Overall median (IQR)  30,000 
(8,000-80,000) 
20,000 
(5,000-50,000) 
P=0.0005 
      
Time taken to reach clinic, median hours (IQR).  1 (0.5-2)  1 (0.75-2)  P=0. 7 
      
Main form of transport used to come to clinic, number (%)       
Walk  21 (5)  46 (4)  P=0.04 
Taxi (bicycle, motorbike, car)  368 (87)  944 (92)   
Own transport (bike, car)  33 (8)  41 (4)   
      
WHO stage, number (%)        
I  5 (1)  15 (1)  P=0.4 
II  173 (41)  469 (45)   
III  208 (49)  464 (45)   
IV  36 (9)  83 (8)   
      
CD4 count x 10
6/1 at enrolment       
< 50   142 (34)   301 (29)   P= 0.06 
50-99  73 (17)   159 (15)    
100-200  164 (39)  482 (47)   
> 200  43 (10)  89 (9)   
      
CD4 count x 10
6/l, median (IQR)  98 
(28-160) 
111 
(36-166) 
P= 0.08 
 
      
Plasma viral load copies/ml, number (%)       
< 1,000  4 (1)  17 (2)  P= 0.0001 
1,000-9,999 8  (2)  32(3)   
10,000-99,999 98  (23)  356(35)   
 100,000-999,999  284 (67)  548 (53)   
>= 1,000,000  28 (7)  78 (8)   
      
Plasma viral load copies/ml, median (IQR)  206,102 
(97,692-460,612) 
147,108 
(52,596-343,416) 
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return to clinic. From February 05, 1488 subjects were 
started on ART. Eleven subjects did not meet the eligibility 
criteria for the trial and the remainder 1477 subjects were 
invited to join the trial. Just 24 refused and the other1453 
were recruited. 
 Table  1 shows the characteristics of the trial cohort at 
baseline. Significantly more women than men were re-
cruited. Women were significantly younger, less educated 
and less likely to be currently married or living with some-
one and less likely to be employed. They were also signifi-
cantly more likely to be renting or living for free and have 
lower income. There was no significant difference in the 
time taken to come to clinic or the means of transport used 
between men and women. 
  The WHO HIV clinical stage at presentation did not dif-
fer significantly between men and women: 58% and 53% 
respectively were at WHO stage III or IV (p=0.9). More men 
presented at lower CD4 count category than women but this 
was not statistically significant (p=0.06, Chi-squared test). 
Women had significantly lower plasma viral loads than men, 
with 40% of women having viral loads below 100,000 copies 
per ml compared to 26% of men (P<0.0001). Twenty-one 
(1%) subjects had undetectable viral load but reported being 
antiretroviral naïve. 
  Women were significantly less likely to disclose to their 
spouses and partners than men. However, they were more 
likely to disclose to children and other household members 
(Table  2). Women were also significantly less likely to 
choose spouses as their medicine companions and more 
likely to choose children than men. The median age (IQR) of 
children who acted as medicine companions was 14 (11-16) 
years for men and 13 (11-15) for women (p=0.2). 
  Understanding of the principles of ART at the time of 
initiation was generally very high except for side effects in 
which only an overall 941/1453 (65%) agreed that the ART 
can make you feel unwell even if the therapy is working. 
None of the knowledge indicators differed significantly be-
tween men and women. Significantly more men than women 
reported drinking alcohol (47/422[11%] vs 80/1031 [8%], 
p=0.04) and having had sexual intercourse in the last 3 
months (183/422 [43%] vs 242/1031 [23%], p<0.0001). 
  The male: female ratio and WHO clinical stage at which 
men and women presented was unchanged over the 2-year 
Table 2.  Levels of Disclosure, Support and Knowledge Among Men and Women at Baseline 
 
  Men Women   
  n. 422  n. 1031   
Disclosed to spouse or partner (among those who had a spouse/partner), number (%)  287/305 (94)  284/347 (82)  P=0.0001 
      
Disclosed to children (among those who have children), number (%)  277/325 (85)  830/910 (91)  P=0.0001 
     
Disclosed to all other household members (among those who have household members), number (%)  317/355 (89)  830/912 (91)  P=0.2 
     
Type of medicine companion chosen       
Spouse/ partner  186 (44)  75 (7)   P< 0.0001 
Biological child  64 (15)   409 (40)    
Other relative /household member  154 (37)  497 (48)    
Neighbour/ friend  14 (3)   47 (5)    
Other  4 (1)   3 (0.3)   
     
Choice of medicine companion if married/have partner       
Spouse/partner  185(66) 73(31)  P<  0.0001 
Biological child  32(12) 85  (36)   
Other relative/household member  55(20)  64 (27)   
Neighbour/friend  5(2) 15  (6)   
Other   2(1) 0   
Total  279/404 (69)  237/1031 (23)   
Once a person reaches full health again, he/she can stop taking ART drugs, number disagree (%)   381 (90)  971 (94.2)  P=0.04 
     
     
419 (99)  1,024 (99)  P=1.0   ART needs to be taken every day for the rest of your life, even if you feel perfectly healthy, number agree (%) 
   
     
Once ART starts working, a person does not need to wear a condom anymore to prevent spreading HIV, num-
ber disagree (%) 
407 (96)  965 (94)  P=0.09 
     
The side effects of ART can make you feel ill, even when the drugs are working well, number agree (%)  274(65)  667 (65)  P= 1.0 
     
It is OK to share ART drugs with others in the family who are sick but didn’t get them, number disagree (%)  417(99)  1,003(97)  P= 0.1 
     
It is better to stop taking ART drugs for a few days to let your body rest once in a while, number disagree (%). 401(95) 963  (93)  P=0.5 A Cluster-Randomised Trial  The Open AIDS Journal, 2007, Volume 1    25 
recruitment (Table 3). There was no association between 
CD4 at presentation and calendar days since the start of the 
trial in men (r= 0.025, p=0.6) and women (r= 0.0022, p=0.9). 
There was a weak association between plasma virus load and 
days since the start of the trial in both men and women (r=-
0.14, p= 0.005 and r=-0.13, p<0.0001 respectively). 
DISCUSSION 
  The roll-out of ART is progressing rapidly in several 
African countries and our trial is designed to inform policy, 
particularly for rural areas where experience with ART is 
most limited. A number of factors could influence the viabil-
ity of the trial. There are an increasing number of ART pro-
viders (e.g. government, NGO’s, church, private clinics), 
some with quotas to fill. We may lose participants for fol-
low-up if their health improves on ART and they migrate for 
work. It is possible that we may have a larger number of 
withdrawals from the home-based arm because of potentially 
increased stigma compared with the facility-based arm, al-
though this is likely to occur around the time of randomisa-
tion. Those in the home arm may also withdraw in greater 
numbers as they resume regular employment and find diffi-
culty with being present at home to meet the field officer. 
The extent of these potential biases is difficult to estimate. 
We have attempted to minimise risk by selecting an area 
which has a stable population, where there is one predomi-
nant ART provider and where stigma is generally low. A 
strength of our trial is that it is in partnership between re-
searchers and the health services and is being conducted in 
close to real life conditions. The results should feed directly 
into policy and, importantly, trial subjects will receive ART 
beyond the lifespan of the research as part of the normal 
health service provision. 
  This study is being conducted in a poor, largely rural and 
semi-urban setting and comprising an unselected cohort of 
subjects coming forward for ART just after ART became 
available for free in the country. Levels of education, em-
ployment, house ownership and income, were low and sig-
nificantly lower among women than among men. The costs 
of transport were very high in relation to income, especially 
for women. Our expectation was that men would access 
ART from TASO in large numbers, given their higher social 
status, income and mobility. However, far more women than 
men accessed the ART service and why men have been re-
luctant to come forward for treatment is unclear. The propor-
tion eligible for ART in the area was probably similar among 
men and women since the epidemic in Uganda is old and the 
prevalence of HIV-infection broadly similar between the two 
sexes [7, 8]. TASO has been very open to both men and 
women since it started treating patients with ART and has 
especially encouraged family members to come forward for 
screening. We know also that TASO was almost the sole 
provider of free ART in the district (less than 100 patients 
were receiving ART from public services during the recruit-
ment period) and so those who did not come forward for 
ART at TASO are unlikely to have been on treatment. It is 
plausible that a higher rate of employment among men than 
women may have made it more difficult for men to come 
forward for ART although unemployment is generally very 
high in our setting and employed people are able to access 
ART from TASO, as is evident from our trial population of 
whom around 75% were working. Data from rural African 
settings are scarce but other sites in Uganda have also re-
ported more women than men accessing ART [9]. This re-
quires further research, ideally in an area where demographic 
surveillance is being conducted and where there is a clear 
understanding of the demography of the population. Africa 
Table 3.  Changes in Baseline Clinical Characteristics Over the Duration of Recruitment into the Study 
 
  Men Women   
      
Male: Female ratio recruited, number (%)       
Feb 2005-Sep 05  134 (28)  338 (72)   
Oct 2005 – May 06  159 (30)  375 (70)   
Jun 06 – Dec 06  129 (29)  318 (71)  P=0.9 
      
CD4 count, median (IQR)       
Feb 2005-Sep 05  87 (28-158)  107 (41-161)   
Oct 2005 – May 06  97 (25-162)  117 (38-168)  P=0.6 
Jun 06 – Dec 06  106 (31-162)  112 (34-171)   
      
Plasma viral load, median (IQR)       
Feb 2005-Sep 05  260,206 
(109,224-595,220) 
172,620 
(61,606-415,428) 
 
Oct 2005 – May 06  182,320 
(92,796-343,608) 
173,988 
(52,716-342,020) 
P<0.0001 
Jun 06 – Dec 06  188,472 
(89,272-372,624) 
125,288 
(45, 792-287,752) 
 
      
WHO clinical stage III & IV, number (%)       
Feb 2005-Sep 05  76/134 (57)  186/338 (55)   
Oct 2005 – May 06  90/159 (57)  186/375 (50)  P=0.2 
Jun 06 – Dec 06  78/129 (60)  175/318 (55)   26    The Open AIDS Journal, 2007, Volume 1  Amuron et al. 
may not see the full benefits of ART unless uptake of ART is 
equitable. 
  The majority of subjects presented for ART with ad-
vanced HIV stage, low CD4 count and high plasma virus 
load throughout the course of the two-year recruitment pe-
riod. Mortality and morbidity are very high when CD4 count 
falls below 200 x 10
6 cells/l and the complications of treat-
ment are greater when patients start therapy at a more ad-
vanced stage. In developed countries, people tend to start 
antiretroviral therapy at around 250 count x 10
6 cells/l or 
higher but there are calls to raise this threshold even higher 
in an attempt to reduce morbidity and mortality further [10]. 
It is vital that attempts are made to initiate ART in Africa 
earlier than at present to ensure that treatment programmes 
are effective in reducing mortality. Earlier initiation may also 
reduce infectiousness of HIV-infected subjects and impact 
on HIV transmission, although this has not been established 
[11]. 
  There was no evidence that when they presented for 
ART, men were at more advanced WHO HIV stage or had 
significantly lower CD4 count than women. Plasma virus 
load was lower in women but lower levels of virus have been 
shown in women than in men  [12, 13]. These indicators did 
not change appreciably over the two years of recruitment for 
either men or women in our study. 
  Overall, disclosure rates were very high in this popula-
tion, and men were more likely to disclose to and select their 
partners as medicine companions while women were more 
likely to disclose to and accept children as their medicine 
companions. There were also high and similar degrees of 
knowledge about the principles of ART reported by both 
men and women, suggesting that it is possible to raise 
awareness and commitment to ART in rural resource-poor 
settings and in populations which have limited levels of edu-
cation. Understanding of side effects was less good than the 
other indicators, but this could be because the terminology 
“side effects” does not translate well into the local language 
and may be difficult to study in a quantitative questionnaire 
format. It will be interesting to see how this level of knowl-
edge translates to adherence and clinical outcomes over time. 
  The costs of plasma viral load testing are so high that 
most African countries, including Uganda, do not test rou-
tinely and are unlikely to afford these for the foreseeable 
future, Consequently, we did not provide real time viral load 
testing. By doing so could influence clinical management 
and the study results would then be less applicable and of 
less value to the situation in Uganda and elsewhere in Africa. 
  In summary, our study shows a significantly higher pro-
portion of women than men accessed ART, and that both 
men and women present for treatment at a late HIV stage. 
Research is required to identify the reasons why men are 
reluctant to access care and to identify ways of reaching and 
treating patients at an earlier HIV stage. Whether the high 
degree of knowledge acquired on ART will translate into 
better adherence and better clinical outcomes remains to be 
seen. 
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